IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Senior management elected to issue restricted common stock at $0.27 per share instead of repaying amounts owed, including repayment of more than $552,362 of personal cash previously advanced to IGC. The action appears administrative/financing-related rather than an operational performance update, with limited near-term guidance on financial impact.

Analysis

Senior management elected to issue restricted common stock at $0.27 per share instead of repaying amounts owed, including repayment of more than $552,362 of personal cash previously advanced to IGC. The action appears administrative/financing-related rather than an operational performance update, with limited near-term guidance on financial impact.